Immunai, an AI-driven biotech company focused on mapping the human immune system, has entered into a partnership with Teva Pharmaceuticals in a multi-year collaboration aimed at improving clinical trial outcomes for oncology and immunology therapies.

The collaboration will leverage Immunai’s proprietary immune cell atlas, AMICA, and its AI-powered Immunodynamics Engine (IDE) to enhance clinical decision-making. The technology is intended to enhance the understanding of drug mechanisms of action, optimise dose selection, and analyse biomarkers to improve trial success rates and patient outcomes.

The companies could also expand the collaboration to cover broader aspects of Teva’s research and development portfolio. The announcement comes after Immunai entered into a multi-year collaboration with AstraZeneca for advanced clinical trial optimisation.